Built for the researcher who has to defend the call.
Euretos Disease Atlas asks causal questions to rank the full protein-coding genome against resolved organ, tissue, and cell-type biology, across 34,000 indications. We built it because target prioritisation should rest on causal evidence at the cell type where the disease operates, not on how often a gene appears in PubMed.
Why we built this
Most target-prioritisation platforms aggregate literature. That works for landscape questions and BD intel. It does not work for the question that decides programmes: which target is most likely to modify this disease, in the compartment where the disease operates? Literature ranks targets by how much has been written about them. Disease Atlas ranks them by causal evidence on primary biological data.
Five evidence layers carry the platform. Mendelian randomisation on GWAS effect sizes, perturbation magnitudes from CRISPR and LINCS, single-cell expression from CellxGene and the Human Cell Atlas, ligand-receptor structure, and protein-protein interaction networks. Each layer answers a specific causal question. The integration uses explicit causal weighting, not a democratic average. No language model sits in the reasoning path; every score traces to a primary biological measurement.
Who we are
Euretos is based in Leiden, the Netherlands, with an office in Boston. The company was co-founded by Arie Baak, co-author of the 2016 FAIR Guiding Principles paper (Wilkinson et al., Scientific Data), the data-management framework now adopted across the EU's life-sciences research infrastructure. That orientation toward findable, accessible, interoperable, and reusable evidence runs through everything we build.
The team brings together computational biologists, data engineers, translational researchers, and application developers. We work upstream of the interpretation layer where LLM-based platforms sit. Our clients run programmes; we give them the evidence to defend the calls they make.
Who we work with
Disease Atlas serves target discovery, target assessment, indication expansion, and search-and-evaluation teams at biotech and pharma. Long-tenured customers are among the largest Biotech and Pharmaceutical companies across the world.
These are the general terms and conditions which apply to the services Euretos provides and the access to the Euretos AI Platform. These may be changed from time to time.
